Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
European Child & Adolescent Psychiatry
Published in: European Child & Adolescent Psychiatry 9/2012

Open Access 01-09-2012 | Review

Amfetamine and methylphenidate medications for attention-deficit/hyperactivity disorder: complementary treatment options

Authors: Paul Hodgkins, Monica Shaw, David Coghill, Lily Hechtman

Published in: European Child & Adolescent Psychiatry | Issue 9/2012

Login to get access

Abstract

Attention-deficit/hyperactivity disorder (ADHD) is one of the most common neurodevelopmental disorders among school-aged children. It is highly symptomatic and associated with significant impairment. This review examines the role of stimulant medications in the treatment of children and adolescents with ADHD. Published clinical studies that compared methylphenidate- and amfetamine-based stimulants in children and adolescents with ADHD support the therapeutic utility of stimulant treatments, and suggest robust efficacy and acceptable safety outcomes in groups treated with either stimulant. Evidence-based guidelines agree that each patient with ADHD is unique and individual treatment strategies that incorporate both drug and non-drug treatment options should be sought. In seeking to optimize individual response and outcomes to stimulant therapy, important considerations include the selection of stimulant class, the choice of long- or short-acting stimulant formulations, addressing effectively any emergent adverse effects and strategies aimed at enhancing adherence to dosing regimen and persistence on therapy.
Literature
1.
American Academy of Pediatrics (2011) ADHD: Clinical Practice Guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics 128:1007–1022CrossRef
2.
American Psychiatric Association (2000) Diagnostic and statistical manual of mental disorders, Fourth Edition, Text Revision (DSM-IV-TR). American Psychiatric Association, Washington DCCrossRef
3.
Antshel KM, Hargrave TM, Simonescu M, Kaul P, Hendricks K, Faraone SV (2011) Advances in understanding and treating ADHD. BMC Med 9:72PubMedCrossRef
4.
Arnold EL (2000) Methylphenidate vs. amphetamine: comparative review. J Atten Disord 3:200–211CrossRef
5.
Arnold LE, Christopher J, Huestis R, Smeltzer DJ (1978) Methylphenidate vs dextroamphetamine vs caffeine in minimal brain dysfunction: controlled comparison by placebo washout design with Bayes’ analysis. Arch Gen Psychiatry 35:463–473PubMedCrossRef
6.
Arnsten AF (2009) The emerging neurobiology of attention deficit hyperactivity disorder: the key role of the prefrontal association cortex. J Pediatr 154:I–S43
7.
Arnsten AF (2006) Fundamentals of attention-deficit/hyperactivity disorder: circuits and pathways. J Clin Psychiatry 67(Suppl 8):7–12PubMed
8.
Assmann SF, Pocock SJ, Enos LE, Kasten LE (2000) Subgroup analysis and other (mis)uses of baseline data in clinical trials. Lancet 355:1064–1069PubMedCrossRef
9.
Banaschewski T, Coghill D, Santosh P, Zuddas A, Asherson P, Buitelaar J, Danckaerts M, Dopfner M, Faraone SV, Rothenberger A, Sergeant J, Steinhausen HC, Sonuga-Barke EJ, Taylor E (2006) Long-acting medications for the hyperkinetic disorders. A systematic review and European treatment guideline. Eur Child Adolesc Psychiatry 15:476–495PubMedCrossRef
10.
Bellgrove MA, Barry E, Johnson KA, Cox M, Daibhis A, Daly M, Hawi Z, Lambert D, Fitzgerald M, McNicholas F, Robertson IH, Gill M, Kirley A (2008) Spatial attentional bias as a marker of genetic risk, symptom severity, and stimulant response in ADHD. Neuropsychopharmacology 33:2536–2545PubMedCrossRef
11.
Bonetti M, Gelber RD (2004) Patterns of treatment effects in subsets of patients in clinical trials. Biostatistics 5:465–481PubMedCrossRef
12.
Borcherding BG, Keysor CS, Cooper TB, Rapoport JL (1989) Differential effects of methylphenidate and dextroamphetamine on the motor activity level of hyperactive children. Neuropsychopharmacology 2:255–263PubMedCrossRef
13.
Brennan AR, Arnsten AF (2008) Neuronal mechanisms underlying attention deficit hyperactivity disorder: the influence of arousal on prefrontal cortical function. Ann N Y Acad Sci 1129:236–245PubMedCrossRef
14.
Brown GL, Hunt RD, Ebert MH, Bunney WE Jr, Kopin IJ (1979) Plasma levels of d-amphetamine in hyperactive children serial behavior and motor responses. Psychopharmacology 62:133–140PubMedCrossRef
15.
16.
Cai T, Tian L, Wong PH, Wei LJ (2011) Analysis of randomized comparative clinical trial data for personalized treatment selections. Biostatistics 12:270–282PubMedCrossRef
17.
18.
Carlson CL, Pelham WE Jr, Milich R, Dixon J (1992) Single and combined effects of methylphenidate and behavior therapy on the classroom performance of children with attention-deficit hyperactivity disorder. J Abnorm Child Psychol 20:213–232PubMedCrossRef
19.
Castellanos FX, Elia J, Kruesi MJ, Marsh WL, Gulotta CS, Potter WZ, Ritchie GF, Hamburger SD, Rapoport JL (1996) Cerebrospinal fluid homovanillic acid predicts behavioral response to stimulants in 45 boys with attention deficit/hyperactivity disorder. Neuropsychopharmacology 14:125–137PubMedCrossRef
20.
Christensen L, Sasane R, Hodgkins P, Harley C, Tetali S (2010) Pharmacological treatment patterns among patients with attention-deficit/hyperactivity disorder: retrospective claims-based analysis of a managed care population. Curr Med Res Opin 26:977–989PubMedCrossRef
21.
22.
23.
Dahabreh IJ, Terasawa T, Castaldi PJ, Trikalinos TA (2011) Systematic review: anti-epidermal growth factor receptor treatment effect modification by KRAS mutations in advanced colorectal cancer. Ann Intern Med 154:37–49PubMed
24.
25.
Dew RE, Kollins SH (2010) Lisdexamfetamine dimesylate: a new option in stimulant treatment for ADHD. Expert Opin Pharmacother 11:2907–2913PubMedCrossRef
26.
Diamond A (2005) Attention-deficit disorder (attention-deficit/hyperactivity disorder without hyperactivity): a neurobiologically and behaviorally distinct disorder from attention-deficit/hyperactivity disorder (with hyperactivity). Dev Psychopathol 17:807–825PubMedCrossRef
27.
Dopheide JA (2009) The role of pharmacotherapy and managed care pharmacy interventions in the treatment of ADHD. Am J Manag Care 15:S141–S150PubMed
28.
Early Breast Cancer Trialists’ Collaborative Group (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687–1717CrossRef
29.
Early Breast Cancer Trialists’ Collaborative Group (1998) Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351:1451–1467CrossRef
30.
Easton N, Steward C, Marshall F, Fone K, Marsden C (2007) Effects of amphetamine isomers, methylphenidate and atomoxetine on synaptosomal and synaptic vesicle accumulation and release of dopamine and noradrenaline in vitro in the rat brain. Neuropharmacology 52:405–414PubMedCrossRef
31.
Efron D, Jarman F, Barker M (1997) Methylphenidate versus dexamphetamine in children with attention deficit hyperactivity disorder: a double-blind, crossover trial. Pediatrics 100:E6PubMedCrossRef
32.
Efron D, Jarman F, Barker M (1997) Side effects of methylphenidate and dexamphetamine in children with attention deficit hyperactivity disorder: a double-blind, crossover trial. Pediatrics 100:662–666PubMedCrossRef
33.
Elia J (2005) Attention deficit/hyperactivity disorder: pharmacotherapy. Psychiatry (Edgmont) 2:27–35
34.
Elia J, Borcherding BG, Potter WZ, Mefford IN, Rapoport JL, Keysor CS (1990) Stimulant drug treatment of hyperactivity: biochemical correlates. Clin Pharmacol Ther 48:57–66PubMedCrossRef
35.
Elia J, Borcherding BG, Rapoport JL, Keysor CS (1991) Methylphenidate and dextroamphetamine treatments of hyperactivity: are there true nonresponders? Psychiatry Res 36:141–155PubMedCrossRef
36.
Elia J, Welsh PA, Gullotta CS, Rapoport JL (1993) Classroom academic performance: improvement with both methylphenidate and dextroamphetamine in ADHD boys. J Child Psychol Psychiatry 34:785–804PubMedCrossRef
37.
Faraone SV (2012) Understanding the effect size of lisdexamfetamine dimesylate for treating ADHD in children and adults. J Atten Disord 16:128–137PubMedCrossRef
38.
Faraone SV (2009) Using meta-analysis to compare the efficacy of medications for attention-deficit/hyperactivity disorder in youths. P T 34:678–694PubMed
39.
Faraone SV, Buitelaar J (2010) Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis. Eur Child Adolesc Psychiatry 19:353–364PubMedCrossRef
40.
Faraone SV, Glatt SJ (2009) A comparison of the efficacy of medications for adult attention-deficit/hyperactivity disorder using meta-analysis of effect sizes. J Clin Psychiatry 71:754–763PubMedCrossRef
41.
Faraone SV, Mick E (2010) Molecular genetics of attention deficit hyperactivity disorder. Psychiatr Clin N Am 33:159–180CrossRef
42.
Fegert JM, Slawik L, Wermelskirchen D, Nubling M, Muhlbacher A (2011) Assessment of parents’ preferences for the treatment of school-age children with ADHD: a discrete choice experiment. Expert Rev Pharmacoecon Outcomes Res 11:245–252PubMedCrossRef
43.
Findling RL (2008) Evolution of the treatment of attention-deficit/hyperactivity disorder in children: a review. Clin Ther 30:942–957PubMedCrossRef
44.
Froehlich TE, McGough JJ, Stein MA (2010) Progress and promise of attention-deficit hyperactivity disorder pharmacogenetics. CNS Drugs 24:99–117PubMedCrossRef
45.
Goodman DW (2010) Lisdexamfetamine dimesylate (vyvanse), a prodrug stimulant for attention-deficit/hyperactivity disorder. P T 35:273–287PubMed
46.
Graham J, Banaschewski T, Buitelaar J, Coghill D, Danckaerts M, Dittmann RW, Dopfner M, Hamilton R, Hollis C, Holtmann M, Hulpke-Wette M, Lecendreux M, Rosenthal E, Rothenberger A, Santosh P, Sergeant J, Simonoff E, Sonuga-Barke E, Wong IC, Zuddas A, Steinhausen HC, Taylor E (2011) European guidelines on managing adverse effects of medication for ADHD. Eur Child Adolesc Psychiatry 20:17–37PubMedCrossRef
47.
Graham J, Coghill D (2008) Adverse effects of pharmacotherapies for attention-deficit hyperactivity disorder: epidemiology, prevention and management. CNS Drugs 22:213–237PubMedCrossRef
48.
Heal DJ, Smith SL, Findling RL (2012) ADHD: current and future therapeutics. Curr Top Behav Neurosci 9:361–390PubMedCrossRef
49.
Heal DJ, Smith SL, Kulkarni RS, Rowley HL (2008) New perspectives from microdialysis studies in freely-moving, spontaneously hypertensive rats on the pharmacology of drugs for the treatment of ADHD. Pharmacol Biochem Behav 90:184–197PubMedCrossRef
50.
Hermens DF, Cooper NJ, Kohn M, Clarke S, Gordon E (2005) Predicting stimulant medication response in ADHD: evidence from an integrated profile of neuropsychological, psychophysiological and clinical factors. J Integr Neurosci 4:107–121PubMedCrossRef
51.
Hungund BL, Perel JM, Hurwic MJ, Sverd J, Winsberg BG (1979) Pharmacokinetics of methylphenidate in hyperkinetic children. Br J Clin Pharmacol 8:571–576PubMedCrossRef
52.
Jones SR, Gainetdinov RR, Wightman RM, Caron MG (1998) Mechanisms of amphetamine action revealed in mice lacking the dopamine transporter. J Neurosci 18:1979–1986PubMed
53.
Kahlig KM, Binda F, Khoshbouei H, Blakely RD, McMahon DG, Javitch JA, Galli A (2005) Amphetamine induces dopamine efflux through a dopamine transporter channel. Proc Natl Acad Sci USA 102:3495–3500PubMedCrossRef
54.
Karapetis CS, Khambata-Ford S, Jonker DJ, O’Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S, Price TJ, Shepherd L, Au HJ, Langer C, Moore MJ, Zalcberg JR (2008) K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359:1757–1765PubMedCrossRef
55.
Kuczenski R, Segal DS (1997) Effects of methylphenidate on extracellular dopamine, serotonin, and norepinephrine: comparison with amphetamine. J Neurochem 68:2032–2037PubMedCrossRef
56.
Lagakos SW (2006) The challenge of subgroup analyses–reporting without distorting. N Engl J Med 354:1667–1669PubMedCrossRef
57.
58.
Lloyd A, Hodgkins P, Dewilde S, Sasané R, Falcner S, SB E (2011) Methylphenidate delivery mechanisms for the treatment of children with attention deficit hyperactivity disorder: Heterogeneity in parent preferences. Int J Technol Assess Health Care 27:215–223PubMedCrossRef
59.
Marcus SC, Wan GJ, Kemner JE, Olfson M (2005) Continuity of methylphenidate treatment for attention-deficit/hyperactivity disorder. Arch Pediatr Adolesc Med 159:572–578PubMedCrossRef
60.
Markowitz JS, DeVane CL, Pestreich LK, Patrick KS, Muniz R (2006) A comprehensive in vitro screening of d-, l-, and dl-threo-methylphenidate: an exploratory study. J Child Adolesc Psychopharmacol 16:687–698PubMedCrossRef
61.
May DE, Kratochvil CJ (2010) Attention-deficit hyperactivity disorder: recent advances in paediatric pharmacotherapy. Drugs 70:15–40PubMedCrossRef
62.
63.
64.
Muhlbacher AC, Rudolph I, Lincke HJ, Nubling M (2009) Preferences for treatment of attention-deficit/hyperactivity disorder (ADHD): a discrete choice experiment. BMC Health Serv Res 9:149PubMedCrossRef
65.
66.
67.
Pappadopulos E, Jensen PS, Chait AR, Arnold LE, Swanson JM, Greenhill LL, Hechtman L, Chuang S, Wells KC, Pelham W, Cooper T, Elliott G, Newcorn JH (2009) Medication adherence in the MTA: saliva methylphenidate samples versus parent report and mediating effect of concomitant behavioral treatment. J Am Acad Child Adolesc Psychiatry 48:501–510PubMedCrossRef
68.
Pelham WE, Aronoff HR, Midlam JK, Shapiro CJ, Gnagy EM, Chronis AM, Onyango AN, Forehand G, Nguyen A, Waxmonsky J (1999) A comparison of ritalin and adderall: efficacy and time-course in children with attention-deficit/hyperactivity disorder. Pediatrics 103:e43PubMedCrossRef
69.
Pelham WE, Gnagy EM, Chronis AM, Burrows-MacLean L, Fabiano GA, Onyango AN, Meichenbaum DL, Williams A, Aronoff HR, Steiner RL (1999) A comparison of morning-only and morning/late afternoon Adderall to morning-only, twice-daily, and three times-daily methylphenidate in children with attention-deficit/hyperactivity disorder. Pediatrics 104:1300–1311PubMedCrossRef
70.
Pelham WE, Gnagy EM, Greiner AR, Hoza B, Hinshaw SP, Swanson JM, Simpson S, Shapiro C, Bukstein O, Baron-Myak C, McBurnett K (2000) Behavioral versus behavioral and pharmacological treatment in ADHD children attending a summer treatment program. J Abnorm Child Psychol 28:507–525PubMedCrossRef
71.
Pelham WE Jr, Carlson C, Sams SE, Vallano G, Dixon MJ, Hoza B (1993) Separate and combined effects of methylphenidate and behavior modification on boys with attention deficit-hyperactivity disorder in the classroom. J Consult Clin Psychol 61:506–515PubMedCrossRef
72.
Pelham WE Jr, Greenslade KE, Vodde-Hamilton M, Murphy DA, Greenstein JJ, Gnagy EM, Guthrie KJ, Hoover MD, Dahl RE (1990) Relative efficacy of long-acting stimulants on children with attention deficit-hyperactivity disorder: a comparison of standard methylphenidate, sustained-release methylphenidate, sustained-release dextroamphetamine, and pemoline. Pediatrics 86:226–237PubMed
73.
Pelham WE Jr, Wheeler T, Chronis A (1998) Empirically supported psychosocial treatments for attention deficit hyperactivity disorder. J Clin Child Psychol 27:190–205PubMedCrossRef
74.
75.
Pliszka S (2007) Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 46:894–921PubMedCrossRef
76.
Pliszka SR, Browne RG, Olvera RL, Wynne SK (2000) A double-blind, placebo-controlled study of Adderall and methylphenidate in the treatment of attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 39:619–626PubMedCrossRef
77.
Pliszka SR, Crismon ML, Hughes CW, Corners CK, Emslie GJ, Jensen PS, McCracken JT, Swanson JM, Lopez M (2006) The Texas Children’s Medication Algorithm Project: revision of the algorithm for pharmacotherapy of attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 45:642–657PubMedCrossRef
78.
Pocock SJ, Assmann SE, Enos LE, Kasten LE (2002) Subgroup analysis, covariate adjustment and baseline comparisons in clinical trial reporting: current practice and problems. Stat Med 21:2917–2930PubMedCrossRef
79.
Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA (2007) The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry 164:942–948PubMedCrossRef
80.
Ramos-Quiroga JA, Bosch R, Castells X, Valero S, Nogueira M, Gomez N, Yelmo S, Ferrer M, Martinez Y, Casas M (2008) Effect of switching drug formulations from immediate-release to extended-release OROS methylphenidate: a chart review of Spanish adults with attention-deficit hyperactivity disorder. CNS Drugs 22:603–611PubMedCrossRef
81.
Reeves G, Anthony B (2009) Multimodal treatments versus pharmacotherapy alone in children with psychiatric disorders: implications of access, effectiveness, and contextual treatment. Paediatr Drugs 11:165–169PubMedCrossRef
82.
Robertson SD, Matthies HJ, Galli A (2009) A closer look at amphetamine-induced reverse transport and trafficking of the dopamine and norepinephrine transporters. Mol Neurobiol 39:73–80PubMedCrossRef
83.
Sanchez RJ, Crismon ML, Barner JC, Bettinger T, Wilson JP (2005) Assessment of adherence measures with different stimulants among children and adolescents. Pharmacotherapy 25:909–917PubMedCrossRef
84.
85.
Seixas M, Weiss M, Muller U (2012) Systematic review of national and international guidelines on attention-deficit hyperactivity disorder. J Psychopharmacol 26:753–765PubMedCrossRef
86.
Sharp WS, Walter JM, Marsh WL, Ritchie GF, Hamburger SD, Castellanos FX (1999) ADHD in girls: clinical comparability of a research sample. J Am Acad Child Adolesc Psychiatry 38:40–47PubMedCrossRef
87.
Solomon SD, Rice MM, Jablonski JA, Jose P, Domanski M, Sabatine M, Gersh BJ, Rouleau J, Pfeffer MA, Braunwald E (2006) Renal function and effectiveness of angiotensin-converting enzyme inhibitor therapy in patients with chronic stable coronary disease in the Prevention of Events with ACE inhibition (PEACE) trial. Circulation 114:26–31PubMedCrossRef
88.
Steele M, Jensen PS, Quinn DM (2006) Remission versus response as the goal of therapy in ADHD: a new standard for the field? Clin Ther 28:1892–1908PubMedCrossRef
89.
Stein MA, McGough JJ (2008) The pharmacogenomic era: promise for personalizing attention deficit hyperactivity disorder therapy. Child Adolesc Psychiatr Clin N Am 17:475–490, xi–xii
90.
Sulzer D, Sonders MS, Poulsen NW, Galli A (2005) Mechanisms of neurotransmitter release by amphetamines: a review. Prog Neurobiol 75:406–433PubMedCrossRef
91.
Taylor E, Dopfner M, Sergeant J, Asherson P, Banaschewski T, Buitelaar J, Coghill D, Danckaerts M, Rothenberger A, Sonuga-Barke E, Steinhausen HC, Zuddas A (2004) European clinical guidelines for hyperkinetic disorder–first upgrade. Eur Child Adolesc Psychiatry 13(Suppl 1):I7–I30PubMed
92.
The MTA Cooperative Group (1999) A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Multimodal treatment study of children with ADHD. Arch Gen Psychiatry 56:1073–1086CrossRef
93.
94.
Tian L, Cai T, Wei LJ (2009) Identifying subjects who benefit from additional information for better prediction of the outcome variables. Biometrics 65:894–902PubMedCrossRef
95.
Volkow ND, Fowler JS, Wang G, Ding Y, Gatley SJ (2002) Mechanism of action of methylphenidate: insights from PET imaging studies. J Atten Disord 6(Suppl 1):S31–S43PubMed
96.
Volkow ND, Wang GJ, Fowler JS, Gatley SJ, Logan J, Ding YS, Hitzemann R, Pappas N (1998) Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate. Am J Psychiatry 155:1325–1331PubMed
97.
Wigal SB, Kollins SH, Childress AC, Squires L (2009) A 13-hour laboratory school study of lisdexamfetamine dimesylate in school-aged children with attention-deficit/hyperactivity disorder. Child Adolesc Psychiatry Ment Health 3:17PubMedCrossRef
98.
Wilson HK, Cox DJ, Merkel RL, Moore M, Coghill D (2006) Effect of extended release stimulant-based medications on neuropsychological functioning among adolescents with attention-deficit/hyperactivity disorder. Arch Clin Neuropsychol 21:797–807PubMedCrossRef
99.
Winsberg BG, Press M, Bialer I, Kupietz S (1974) Dextroamphetamine and methylphenidate in the treatment of hyperactive-aggressive children. Pediatrics 53:236–241PubMed
100.
Wolraich ML, Doffing MA (2004) Pharmacokinetic considerations in the treatment of attention-deficit hyperactivity disorder with methylphenidate. CNS Drugs 18:243–250PubMedCrossRef
101.
102.
Zhao L, Cai T, Tian L, Uno H, Solomon SD, Wei LJ (2010) Stratifying subjects for treatment selection with censored event time data from a comparative study. Harvard University Biostatistics Working Paper Series 2010:Working Paper 122
Metadata
Title
Amfetamine and methylphenidate medications for attention-deficit/hyperactivity disorder: complementary treatment options
Authors
Paul Hodgkins
Monica Shaw
David Coghill
Lily Hechtman
Publication date
01-09-2012
Publisher
Springer-Verlag
Published in
European Child & Adolescent Psychiatry / Issue 9/2012
Print ISSN: 1018-8827
Electronic ISSN: 1435-165X
DOI
https://doi.org/10.1007/s00787-012-0286-5

Other articles of this Issue 9/2012

European Child & Adolescent Psychiatry 9/2012 Go to the issue

Original Contribution

Adolescent sexual victimization: a prospective study on risk factors for first time sexual assault

Editorial

Someone is not listening to the facts: there is little psychiatry outside child and adolescent psychiatry

Original Contribution

Adolescent nonsuicidal self-injury: the effects of personality traits, family relationships and maltreatment on the presence and severity of behaviours

Letter to the Editor

Drug-induced acute psychosis in an adolescent first-time user of 4-HO-MET

Original Contribution

Traits of ADHD and autism in girls with a twin brother: a Mendelian randomization study

ESCAP Communications

Communications of the European Society for Child and Adolescent Psychiatry